Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Prognostic value of ebv markers in the clinical management of nasopharyngeal carcinoma (NPC): A multicenter follow‐up study
International Journal of Cancer, Volume 42, No. 2, Year 1988
Notification
URL copied to clipboard!
Description
Between December 1979 and April 1982, 373 patients with untreated, undifferentiated carcinoma of the nasopharynx (NPC), 99 in Hong Kong, 120 in Tunis and 154 in Villejuif, entered a longitudinal study aimed at determining the clinical prognostic value of EBV serology after radiotherapy. A minimum of 3 years' follow‐up was achieved for 319 patients (83 in Tunis, 95 in Hong Kong and 141 in Villejuif) who had regular clinical and serological testing at intervals of 6–8 months. No significant difference in initial serology (i. e., before any treatment) or variations of antibody titers at time of first followup was observed between patients who achieved complete remission after radiotherapy and those who did not. This included IgG and IgA antibodies to VCA, EA or EBNA. However, when patients with confirmed clinical remission I year after completion of radiotherapy were studied, the value of IgG/EA and mainly of IgA/EA increasing titers became highly significant for prediction of relapse, regardless of the initial titers. This demonstrated the clinical usefulness of EBV serology for NPC patients who have confirmed clinical remission after radiotherapy. Copyright © 1988 Wiley‐Liss, Inc., A Wiley Company
Authors & Co-Authors
De Vathaire, Florent
France, Villejuif
Institut de Cancerologie Gustave Roussy
Sancho‐Garner, H.
France, Villejuif
Institut de Cancerologie Gustave Roussy
de Thȩ, Hugues B.
France, Villejuif
Institut de Cancerologie Gustave Roussy
Pieddeloup, C.
France, Villejuif
Institut de Cancerologie Gustave Roussy
Schwaab, Guy
France, Villejuif
Institut de Cancerologie Gustave Roussy
Ho, John H.C.
China, Hong Kong
Queen Elizabeth Hospital Hong Kong
Ellouz, Ridha
Tunisia, Tunis
Institut Salah Azaiez de Tunis
Micheau, Christian
France, Villejuif
Institut de Cancerologie Gustave Roussy
Cammoun, Mohamed
Tunisia, Tunis
Institut Salah Azaiez de Tunis
Cachin, Yves
France, Villejuif
Institut de Cancerologie Gustave Roussy
De-Thé, Guy B.
France, Villeurbanne
Université Claude Bernard Lyon 1
Statistics
Citations: 108
Authors: 11
Affiliations: 4
Identifiers
Doi:
10.1002/ijc.2910420206
ISSN:
00207136
e-ISSN:
10970215
Research Areas
Cancer
Study Design
Cohort Study
Study Approach
Quantitative